irld-34 Antibody

What is the IRLD-34 antibody and what is its target in C. elegans?

The IRLD-34 antibody is a polyclonal antibody developed against the insulin receptor-like domain protein 34 (IRLD-34) in Caenorhabditis elegans. This antibody specifically recognizes recombinant C. elegans IRLD-34 protein (UniProt accession number Q03599). It is generated in rabbits using purified recombinant IRLD-34 protein as the immunogen, resulting in IgG-class antibodies that bind specifically to epitopes present on the target protein . The antibody is primarily used in C. elegans research to study insulin-like signaling pathways and receptor function.

What are the optimal storage conditions for IRLD-34 antibody?

For optimal preservation of IRLD-34 antibody activity, the recommended storage conditions are:

• Long-term storage: -20°C to -80°C

• Avoid repeated freeze-thaw cycles which can degrade antibody quality

• The antibody is typically supplied in a buffer containing preservatives (such as 0.03% Proclin 300)

• For working solutions, store at 2-8°C for up to one month

• The antibody is typically provided in a liquid formulation containing glycerol (often 50%) to prevent freeze-thaw damage

What are the validated applications for IRLD-34 antibody in C. elegans research?

Based on available data, the IRLD-34 antibody has been validated for the following experimental applications:

• ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative detection of the target protein

• Western Blotting (WB): For detection of denatured IRLD-34 protein

When designing experiments with this antibody, researchers should consider:

• Optimal dilutions must be determined empirically for each application

• Positive and negative controls should be included to validate specificity

• The antibody is intended for research use only, not diagnostic applications

What is the recommended protocol for Western blot analysis using IRLD-34 antibody?

While specific optimization is required for each laboratory setting, a general Western blot protocol for IRLD-34 antibody includes:

• Sample preparation:

  • Prepare C. elegans protein extracts using standard methods (e.g., sonication, freeze-thaw)

  • Include appropriate positive controls

• Gel electrophoresis and transfer:

  • Separate proteins on 10-12% SDS-PAGE gels

  • Transfer to PVDF or nitrocellulose membrane

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Dilute primary IRLD-34 antibody (optimal dilution typically between 1:500-1:2000)

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3-5 times with TBST

• Detection:

  • Incubate with HRP-conjugated anti-rabbit secondary antibody

  • Visualize using appropriate chemiluminescent detection reagents

Note: Always perform preliminary titration experiments to determine optimal antibody concentration for your specific experimental conditions.

How can researchers validate the specificity of IRLD-34 antibody in their experimental systems?

Validating antibody specificity is crucial for meaningful research outcomes. For IRLD-34 antibody, consider these approaches:

• Positive controls:

  • Use purified recombinant IRLD-34 protein

  • Test samples with known IRLD-34 expression

• Negative controls:

  • Test in irld-34 knockout or RNAi-treated C. elegans samples

  • Pre-absorption controls: Pre-incubate antibody with excess purified antigen before use

• Cross-reactivity assessment:

  • Test against closely related IRLD family proteins

  • Verify signal absence in non-expressing tissues

• Multiple detection methods:

  • Compare results across different applications (WB, ELISA)

  • Validate with orthogonal techniques (RT-PCR, RNA-seq data)

What are common troubleshooting strategies when working with IRLD-34 antibody?

When encountering difficulties with IRLD-34 antibody experiments, consider these troubleshooting approaches:

How can IRLD-34 antibody be optimized for immunohistochemistry in C. elegans tissues?

While not explicitly validated for immunohistochemistry (IHC) in the provided information, researchers interested in adapting IRLD-34 antibody for this application should consider:

• Fixation optimization:

  • Compare multiple fixatives (paraformaldehyde, Bouin's, methanol/acetone)

  • Test different fixation durations and temperatures

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (citrate buffer, pH 6.0)

  • Enzymatic retrieval (proteinase K)

  • Test multiple retrieval conditions

• Detection system optimization:

  • Compare direct fluorescent conjugates vs. multi-step detection

  • Evaluate signal amplification methods (tyramide signal amplification)

• Validation strategies:

  • Co-localization with known markers

  • Comparison with mRNA expression patterns

  • Confirmation with fluorescent reporter strains

What approaches can be used to analyze IRLD-34 expression across different developmental stages in C. elegans?

For developmental studies of IRLD-34 expression, researchers should consider:

• Stage-specific sample collection:

  • Synchronize worm populations using standard methods

  • Collect samples at key developmental timepoints (embryo, L1-L4, adult)

• Quantitative analysis methods:

  • Western blot with densitometry for relative quantification

  • Quantitative ELISA for absolute quantification

  • Compare protein levels with developmental transcriptome data

• Spatial expression analysis:

  • Optimize IHC protocols for different developmental stages

  • Consider tissue-specific extraction methods

  • Combine with transgenic reporter strains

• Experimental design considerations:

  • Include appropriate loading controls for each developmental stage

  • Account for total protein content differences between stages

  • Incorporate biological and technical replicates

How does IRLD-34 relate to insulin signaling pathways in C. elegans compared to other model organisms?

While specific information about IRLD-34's role is limited in the provided sources, researchers should consider:

• Evolutionary context:

  • C. elegans contains approximately 40 insulin-like peptides (ILPs) and several receptor-like proteins

  • IRLD family proteins may represent divergent insulin receptor-related molecules

  • Compare homology with insulin receptor domains across species

• Functional considerations:

  • Potential role in metabolism, development, or stress response

  • Possible functional redundancy with other IRLD family members

  • Integration with DAF-2 (the canonical insulin receptor) signaling

• Experimental approaches:

  • RNAi or CRISPR-based functional studies combined with antibody detection

  • Co-immunoprecipitation to identify binding partners

  • Phosphorylation studies to examine signaling activity

What methodological considerations are important when using antibodies like IRLD-34 in multi-omics research approaches?

When integrating antibody-based detection with other omics approaches:

• Sample preparation harmonization:

  • Develop protocols compatible with multiple downstream analyses

  • Consider protein-RNA co-extraction methods

  • Implement consistent sample handling across techniques

• Data integration strategies:

  • Correlate protein levels with transcriptomic data

  • Integrate with metabolomic profiles in insulin signaling studies

  • Develop computational frameworks for multi-omics data integration

• Technical validation across platforms:

  • Verify consistency between antibody-based quantification and MS-based proteomics

  • Cross-validate with orthogonal techniques

  • Implement appropriate normalization methods

• Experimental design considerations:

  • Include shared controls across platforms

  • Account for different dynamic ranges between techniques

  • Consider temporal aspects of transcript vs. protein expression

What reporting standards should researchers follow when publishing work using IRLD-34 antibody?

For reproducible research with antibodies, adhere to these reporting standards:

• Complete antibody information:

  • Full product details (manufacturer, catalog number, lot number)

  • Clone type (polyclonal) and host species (rabbit)

  • RRID (Research Resource Identifier) when available

• Validation evidence:

  • Document specificity tests performed

  • Include representative images of controls

  • Report all optimization steps

• Methodological details:

  • Complete protocols with all buffer compositions

  • Antibody dilutions and incubation conditions

  • Image acquisition and analysis parameters

• Limitations disclosure:

  • Acknowledge potential cross-reactivity

  • Note any inconsistent results

  • Discuss alternative interpretations of findings

Following these guidelines ensures research reproducibility and facilitates method adoption by other laboratories .

What emerging techniques might enhance the utility of IRLD-34 antibody in C. elegans research?

Researchers should consider these emerging approaches:

• Advanced imaging applications:

  • Super-resolution microscopy for subcellular localization

  • Expansion microscopy for improved spatial resolution in C. elegans

  • Live-cell imaging with membrane-permeable antibody fragments

• Single-cell applications:

  • Adaptation for single-cell western blotting

  • Integration with single-cell proteomics approaches

  • Development of highly sensitive detection methods

• Antibody engineering approaches:

  • Generation of recombinant antibody fragments

  • Development of nanobodies against specific epitopes

  • Creation of bifunctional antibody reagents for proximity labeling

• Novel functional applications:

  • Intrabody approaches for protein function disruption

  • Targeted protein degradation using antibody-based techniques

  • Combinatorial approaches with CRISPR-based genome editing

These emerging methods could expand the utility of IRLD-34 antibody beyond traditional applications and enable new experimental paradigms in C. elegans research.